bet 12

bet 12

President-elect Donald Trump has filled the key posts for his second term in office, prioritizing loyalty to him after he felt bruised and hampered by internal squabbling during his first term. Some of his choices could face difficult confirmation fights in the Senate, even with Republicans in control, and one candidate has already withdrawn from consideration. Former Florida Rep. Matt Gaetz was Trump's initial pick for attorney general, but he ultimately withdrew following scrutiny over a federal sex trafficking investigation he was embroiled in. Here's a look at Trump's choices: Trump would turn a former critic into an ally as the nation's top diplomat. Rubio , 53, is a noted hawk on China, Cuba and Iran, and was a finalist to be Trump's running mate before the slot went to JD Vance. Rubio is vice chairman of the Senate Intelligence Committee and a member of the Senate Foreign Relations Committee. His selection punctuates the hard pivot Rubio has made with Trump, whom the senator once called a “con man" during his own unsuccessful campaign for the 2016 Republican presidential nomination. Their relationship improved dramatically while Trump was in the White House. Hegseth , 44, was a co-host of Fox News Channel’s “Fox and Friends Weekend” and had been a contributor with the network since 2014. He developed a friendship with Trump, who made regular appearances on the show. Hegseth served in the Army National Guard from 2002 to 2021, deploying to Iraq in 2005 and Afghanistan in 2011 and earning two Bronze Stars. He lacks senior military and national security experience and would oversee global crises ranging from Europe to the Middle East. A woman told police that she was sexually assaulted in 2017 by Hegseth after he took her phone, blocked the door to a California hotel room and refused to let her leave, according to a detailed investigative report recently made public. Hegseth told police at the time that the encounter had been consensual and has denied any wrongdoing. Bessent , 62, is a former money manager for George Soros , a big Democratic donor, and an advocate for deficit reduction . He founded the hedge fund Key Square Capital Management after having worked on and off for Soros Fund Management since 1991. If confirmed by the Senate, Bessent would be the nation’s first openly gay treasury secretary. He told Bloomberg in August that he decided to join Trump’s campaign in part to attack the mounting U.S. national debt. That would include slashing government programs and other spending. Gabbard, 43, is a former Democratic House member from Hawaii who has been accused of echoing Russian propaganda. She unsuccessfully sought the party’s 2020 presidential nomination and left the party in 2022. Gabbard endorsed Trump in August and campaigned often with him. Gabbard has served in the Army National Guard for more than two decades and deployed to Iraq and Kuwait. If confirmed she would come to the role as an outsider compared to her predecessor. The current director, Avril Haines, spent several years in top national security and intelligence positions. Bondi , 59, was Florida's first female attorney general, serving between 2011 and 2019. She was on Trump’s legal team during his first impeachment trial in 2020. Considered a loyalist , Bondi also has served with the America First Policy Institute, a Trump-allied group that has helped lay the groundwork for his future administration. Bondi was among a group of Republicans who showed up to support Trump at his hush-money criminal trial in New York that ended in May with a conviction on 34 felony counts. A fierce defender of Trump, she also frequently appeared on Fox News and has been critical of the criminal cases against him. The Republican U.S. House member narrowly lost her reelection bid on Nov. 5 but had received strong backing from union members in her district. As a potential labor secretary, Chavez-DeRemer would oversee the department's workforce and budget and put forth priorities that affect workers’ wages, health and safety, ability to unionize, and employer’s rights to fire employers, among other responsibilities. Chavez-DeRemer is one of a few House Republicans to endorse the “Protecting the Right to Organize” or PRO Act that would allow more workers to conduct organizing campaigns and penalize companies that violate workers’ rights. The act would also weaken “right-to-work” laws in more than half the states. Lutnick heads the brokerage and investment bank Cantor Fitzgerald and is a cryptocurrency enthusiast. He is co-chair of Trump's transition operation, charged along with Linda McMahon, a former wrestling executive who previously led Trump’s Small Business Administration, with helping the president-elect fill key jobs in his second administration. As secretary, Lutnick would play a key role in carrying out Trump's plans to raise and enforce tariffs. He would oversee a sprawling Cabinet department whose oversight ranges from funding new computer chip factories and imposing trade restrictions to releasing economic data and monitoring the weather. Noem is a well-known conservative who used her two terms as South Dakota's governor to vault to a prominent position in Republican politics. During the COVID-19 pandemic, Noem did not order restrictions like other states, instead declaring South Dakota “open for business.” More recently, Noem faced sharp criticism for writing in her memoir about shooting and killing her dog. She is set to lead a department crucial to the president-elect’s hardline immigration agenda as well as other missions. Homeland Security oversees natural disaster response, the U.S. Secret Service and Transportation Security Administration agents who work at airports. Ratcliffe , a former U.S. House member from Texas, was director of national intelligence during the final year and a half of Trump’s first term. He led U.S. government’s spy agencies during the coronavirus pandemic. If confirmed, Ratcliffe will have held the highest intelligence positions in the U.S. Kennedy , 70, ran for president as a Democrat, then as an independent before he dropped out and then endorsed Trump . He's the son of Democratic icon Robert F. Kennedy, who was assassinated in 1968 during his own presidential campaign. Kennedy's nomination alarmed people who are concerned about his record of spreading unfounded fears about vaccines . For example, he has long advanced the debunked idea that vaccines cause autism. Rollins , 52, is president and CEO of the America First Policy Institute, a group helping to lay the groundwork for Trump's second administration. She is a Texas attorney who was Trump's domestic policy adviser and director of his office of American innovation during his first term. Rollins previously was an aide to former Texas Gov. Rick Perry , who also served in Trump's first term. Rollins also ran the Texas Public Policy Foundation. Duffy is a former House member from Wisconsin who was one of Trump's most visible defenders on cable news. Duffy served in the House for nearly nine years , sitting on the Financial Services Committee and chairing the subcommittee on insurance and housing. He left Congress in 2019 for a TV career and has been the host of “The Bottom Line” on Fox Business. Before entering politics, Duffy was a reality TV star on MTV, where he met his wife, “Fox and Friends Weekend” co-host Rachel Campos-Duffy. They have nine children. Collins is a former Republican congressman from Georgia who gained recognition for defending Trump during his first impeachment trial. Trump was impeached for urging Ukraine to investigate Joe Biden in 2019 during the Democratic presidential campaign, but was acquitted by the Senate. Collins also served in the armed forces himself. He is a chaplain in the United States Air Force Reserve Command. The North Dakota governor , 68, is a former Republican presidential primary contender who endorsed Trump after he dropped out of the running. Burgum then became a serious contender to be Trump’s vice presidential choice in part because of his executive experience and business savvy. He also has close ties to deep-pocketed energy industry CEOs. Trump said Burgum would chair a new National Energy Council and have a seat on the National Security Council, which would be a first for the Interior secretary. A campaign donor and CEO of Denver-based Liberty Energy, Wright is a vocal advocate of oil and gas development, including fracking — a key pillar of Trump’s quest to achieve U.S. “energy dominance” in the global market. He also has been one of the industry’s loudest voices against efforts to fight climate change. Wright said the climate movement around the world is “collapsing under its own weight.” The Energy Department is responsible for advancing energy, environmental and nuclear security of the United States. McMahon, a billionaire professional wrestling mogul , would make a return appearance in a second Trump administration. She led the Small Business Administration from 2017 to 2019 in Trump’s first term and twice ran unsuccessfully in Connecticut as a Republican candidate for the U.S. Senate. She served on the Connecticut Board of Education for a year starting in 2009 and has spent years on the board of trustees for Sacred Heart University. She has expressed support for charter schools and school choice. Zeldin does not appear to have any experience in environmental issues, but is a longtime supporter of the former president. The 44-year-old former U.S. House member from New York wrote on X , “We will restore US energy dominance, revitalize our auto industry to bring back American jobs, and make the US the global leader of AI" and "we will do so while protecting access to clean air and water.” Trump often attacked the Biden administration’s promotion of electric vehicles, and incorrectly referred to a tax credit for EV purchases as a government mandate. Trump also often said his administration would “drill, baby, drill,” referring to his support for expanded petroleum exploration. Turner is a former NFL player and White House aide. He ran the White House Opportunity and Revitalization Council during Trump’s first term in office. Trump, in a statement, credited Turner, the highest-ranking Black person he’s yet selected for his administration, with “helping to lead an Unprecedented Effort that Transformed our Country’s most distressed communities.” Greer is a partner at King & Spalding, a Washington law firm. If confirmed by the Senate, he would be responsible for negotiating directly with foreign governments on trade deals and disputes, as well as memberships in international trade bodies such as the World Trade Organization. He previously was chief of staff to Robert Lighthizer, who was the trade representative in Trump's first term. Wiles , 67, was a senior adviser to Trump’s 2024 presidential campaign and its de facto manager. She has a background in Florida politics , helping Ron DeSantis win his first race for Florida governor. Six years later, she was key to Trump’s defeat of him in the 2024 Republican primary. Wiles’ hire was Trump’s first major decision as president-elect and one that could be a defining test of his incoming administration considering her close relationship with him. Wiles is said to have earned Trump’s trust in part by guiding what was the most disciplined of Trump’s three presidential campaigns. Waltz is a three-term Republican congressman from east-central Florida. A former Army Green Beret , he served multiple tours in Afghanistan and worked in the Pentagon as a policy adviser when Donald Rumsfeld and Robert Gates were defense chiefs. He is considered hawkish on China, and called for a U.S. boycott of the 2022 Winter Olympics in Beijing due to its involvement in the origin of COVID-19 and its mistreatment of the minority Muslim Uighur population. Hassett, 62, is a major advocate of tax cuts who was chairman of the Council of Economic Advisers in the first Trump term. In the new role as chairman of the National Economic Council, Trump said Hassett will play an important role in helping American families recover from inflation as well as in renewing and improving tax cuts Trump enacted in 2017, many of which are set to expire after 2025. Homan, 62, has been tasked with Trump’s top priority of carrying out the largest deportation operation in the nation’s history. He led the U.S. Immigration and Customs Enforcement in Trump's first administration. Democrats have criticized Homan for defending Trump’s “zero tolerance” policy on border crossings in the first term, which led to the separation of thousands of parents and children seeking asylum at the border. Vought, 48, held the position during Trump’s first presidency. He the founded the Center for Renewing America, a think tank that describes its mission as “renew a consensus of America as a nation under God.” Vought also was closely involved with Project 2025 , a conservative blueprint for Trump’s second term that Trump tried to distance himself from during the campaign. Miller, an immigration hardliner , was a vocal spokesperson during the presidential campaign for Trump’s priority of mass deportations. The 39-year-old was a senior adviser during Trump’s first term. Miller has been a central figure in some of Trump’s policy decisions, notably his move to separate thousands of immigrant families. Trump argued throughout the campaign that the nation’s economic, national security and social priorities could be met by deporting people living illegally in the U.S. Scavino was an adviser in all three of the president-elect's campaigns and was described by the transition team as one of “Trump’s longest serving and most trusted aides." He will be deputy chief of staff and assistant to the president. Scavino previously ran Trump’s social media profile in the White House. Blair was political director for Trump’s 2024 campaign and for the Republican National Committee. He will be deputy chief of staff for legislative, political and public affairs and an assistant to the president. Blair was key to Trump’s economic messaging during his winning White House comeback campaign. Budowich is a veteran Trump campaign aide who launched and directed Make America Great Again, Inc., a super PAC that supported Trump’s 2024 campaign. He will be deputy chief of staff for communications and personnel and assistant to the president. Leavitt , 27, was Trump's campaign press secretary and currently a spokesperson for his transition. She would be the youngest White House press secretary in history. Leavitt worked in the White House press office during Trump's first term. In 2022, she ran for Congress in New Hampshire, winning a 10-way Republican primary before losing to Democratic Rep. Chris Pappas. McGinley was Cabinet secretary during Trump's first administration and was outside legal counsel for the Republican National Committee's election integrity effort during the 2024 campaign. The 67-year-old Witkoff is the president-elect's golf partner and they were golfing at Trump's club in West Palm Beach, Florida, on Sept. 15, when the former president was the target of a second attempted assassination. Trump also named Witkoff co-chair, with former Georgia Sen. Kelly Loeffler, of his inaugural committee. Kellogg , 80, is a highly decorated retired three-star general and one of the architects of a staunchly conservative policy book that lays out an “America First” national security agenda for Trump's second term. He has long been Trump’s top adviser on defense issues and served as national security adviser to Vice President Mike Pence . Kellogg also was chief of staff of the National Security Council under Trump and stepped in as an acting national security adviser for Trump after Michael Flynn resigned the post. Huckabee is a staunch defender of Israel and his intended nomination comes as Trump has promised to align U.S. foreign policy more closely with Israel's interests. Huckabee, who ran unsuccessfully for the Republican presidential nomination in 2008 and 2016, has been a popular figure among evangelical Christian conservatives, many of whom support Israel due to Old Testament writings that Jews are God’s chosen people and that Israel is their rightful homeland. Huckabee has rejected a Palestinian homeland in territory occupied by Israel. His daughter, Sarah Huckabee Sanders, served as White House press secretary in Trump's first term. Stefanik, 40, is a U.S. representative from New York and one of Trump's staunchest defenders dating to his first impeachment trial. She was elected chair of the House Republican Conference in 2021, the third-highest position in House leadership, after then-Rep. Liz Cheney was removed from the post after she publicly criticized Trump for falsely claiming he won the 2020 election. Stefanik’s questioning of university presidents over antisemitism on their campuses helped lead to two of those presidents resigning, further raising her national profile. A former acting attorney general during Trump's first administration and tight end on the University of Iowa football team, Whitaker , 55, has a background in law enforcement but not in foreign policy. A fierce Trump localist, Whitaker, is also a former U.S. attorney in Iowa and served as acting attorney general between November 2018 and February 2019 without Senate confirmation, until William Barr was confirmed for the role. That was when special counsel Robert Mueller’s investigation into Russian election interference was drawing to a close. Whitaker also faced questions about his past business dealings, including his ties to an invention-promotion company that was accused of misleading consumers. A Republican congressman from Michigan who served from 1993 to 2011, Hoekstra was ambassador to the Netherlands during Trump's first term. Oz , 64, is a former heart surgeon who hosted “The Dr. Oz Show,” a long-running daytime TV talk show. He ran unsuccessfully for the U.S. Senate as the Republican nominee in 2022 and is an outspoken supporter of Trump, who endorsed Oz’s bid for elected office. Makary is a Johns Hopkins surgeon and author who argued against pandemic lockdowns. He routinely appeared on Fox News during the COVID-19 pandemic and wrote opinion articles questioning masks for children. He cast doubt on vaccine mandates but supported vaccines generally. Makary also cast doubt on whether booster shots worked, which was against federal recommendations on the vaccine. Nesheiwat is a general practitioner who serves as medical director for CityMD, a network of urgent care centers in New York and New Jersey. She has been a contributor on Fox News. Weldon is a former Florida congressman who recently ran for a Florida state legislative seat and lost; Trump backed Weldon’s opponent. In Congress, Weldon weighed in on one of the nation’s most heated debates of the 1990s over quality of life and a right-to-die and whether Terri Schiavo, who was in a persistent vegetative after cardiac arrest, state should have been allowed to have her feeding tube removed. He sided with the parents who did not want it removed. Bhattacharya , 56, is a critic of pandemic lockdowns and vaccine mandates. As head of the NIH, the leading medical research agency in the United States, Trump said Bhattacharya would work with Kennedy Jr. to direct U.S. medical research and make important discoveries that will improve health and save lives. Bhattacharya is professor at Stanford University School of Medicine and was one of three authors of the Great Barrington Declaration, an October 2020 open letter maintaining that lockdowns during the COVID-19 pandemic were causing irreparable harm. Gaetz, 42, withdrew from consideration to become the top law enforcement officer of the United States amid fallout over a federal sex trafficking investigation that cast doubt on his ability to be confirmed by the Senate. In choosing Gaetz, Trump had passed over more established lawyers whose names had been floated as possible contenders for the job. Gaetz resigned from Congress after Trump announced him on Nov. 13. The House Ethics Committee has been investigating an allegation that he paid for sex with a 17-year-old. Gaetz has denied wrongdoing. Associated Press writers Colleen Long, Zeke Miller, Farnoush Amiri, Lolita C. Baldor, Jill Colvin, Matthew Daly, Edith M. Lederer, Adriana Gomez Licon, Lisa Mascaro, Chris Megerian, Michelle L. Price, Will Weissert and Darlene Superville contributed to this report.NoneNoneGREENSBORO, N.C. (AP) — Matthew Downing threw for two touchdowns and ran for another to lead Elon to a 31-21 season-ending win over North Carolina A&T on Saturday. The game was tied at 7 in the second quarter when the Phoenix turned a fumble recovery into a field goal. That started a string of four-straight scoring possessions. Downing was 16 of 21 for 203 yards. Chandler Brayboy had 12 receptions for 118 yards with a score. Rushawn Baker ran for 106 yards for the Phoenix (6-6, 5-3 Coastal Athletic Association). Julian Bumper also had a 10-yard rushing touchdown on his only carry and Jamarien Dalton had a 30-yard receiving touchdown on his only catch. Freshman Cortez Lane returned a kickoff 97 yards for a touchdown for the Aggies (1-11, 0-8), who lost their 11th straight. Justin Fomby threw for 190 yards and a touchdown pass to Daniel Cole and Shimique Blizzard ran for 87 yards and a TD. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25

House Representative Nancy Mace announced plans to introduce legislation that would bar transgender women from using women's restrooms and changing rooms in the Captial. This comes after Delaware elected Sarah McBride, the first transgender member of congress, to represent them in D.C. Zoey Tur, a transgender journalist and helicopter pilot, joins CNN's Michael Smerconish to discuss the latest controversy happening in the House and how it is affecting the larger narrative.

Nets Rising Star Expected to Miss 3-4 Weeks

Progressive policies can prevail despite setbacks

SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Stitch Fix, Inc. (NASDAQ: SFIX), the leading online personal styling service, today announced its financial results for the first quarter of fiscal year 2025, ended November 2, 2024. "Our fiscal year is off to a strong start. We exceeded our expectations in the first quarter on the top and bottom lines,” said Matt Baer, Chief Executive Officer, Stitch Fix. "Our clients are responding to the newness we have brought to our assortment as well as the improvements we've made to our client experience. This progress is a testament to the Stitch Fix team's ongoing execution of our transformation strategy, and we continue to expect to return to revenue growth by the end of FY26.” During the first quarter of fiscal 2024, we ceased operations of our UK business and met the accounting requirements for reporting the UK business as a discontinued operation. Accordingly, our unaudited condensed consolidated financial statements reflect the results of the UK business as a discontinued operation for all periods presented. Unless otherwise noted, amounts and disclosures below relate to our continuing operations. First Quarter Fiscal 2025 Key Metrics and Financial Highlights Our financial outlook for the second quarter of fiscal 2025, ending February 1, 2025, is as follows: Our financial outlook for fiscal year 2025 is as follows: We expect both the second quarter and full fiscal year 2025 gross margin to be approximately 44% to 45%, and full fiscal year 2025 advertising expense as a percentage of revenue to be at the high end of an 8% to 9% range. Stitch Fix has not reconciled its Adjusted EBITDA outlook to GAAP net income (loss) because it does not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of restructuring and other one-time costs, net other income (expense), provision for income taxes, and stock-based compensation expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because Stitch Fix cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For more information regarding the non-GAAP financial measures discussed in this release, please see "Non-GAAP Financial Measures” below. Conference Call and Webcast Information Matt Baer, Chief Executive Officer of Stitch Fix, and David Aufderhaar, Chief Financial Officer of Stitch Fix, will host a conference call at 2:00 p.m. Pacific Time today to discuss the Company's financial results and outlook. A live webcast of the call will be accessible on the investor relations section of the Stitch Fix website at https://investors.stitchfix.com . To access the call by phone, please register at the following link: Dial-In Registration: https://register.vevent.com/register/BIb75f616c9a2a4320adf40088c7b87810 Upon registration, telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the webcast will also be available for a limited time at https://investors.stitchfix.com . About Stitch Fix, Inc. Stitch Fix (NASDAQ: SFIX) is the leading online personal styling service that helps people discover the styles they will love that fit perfectly so they always look - and feel - their best. Few things are more personal than getting dressed, but finding clothing that fits and looks great can be a challenge. Stitch Fix solves that problem. By pairing expert stylists with best-in-class AI and recommendation algorithms, the company leverages its assortment of exclusive and national brands to meet each client's individual tastes and needs, making it convenient for clients to express their personal style without having to spend hours in stores or sifting through endless choices online. Stitch Fix, which was founded in 2011, is headquartered in San Francisco. For more information, please visit https://www.stitchfix.com . Forward-Looking Statements This press release, the related conference call, and webcast contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward looking, including but not limited to statements regarding our expectations for future financial performance, including our profitability and long-term targets; guidance on financial results and metrics for the second quarter and full fiscal year of 2025; that the execution of our strategy and priorities will enable us to achieve long-term, sustainable, and profitable growth and positive free cash flow; our expectation to return to revenue growth by the end of fiscal year 2026; that the changes we have made to our client experience will help us acquire, retain, and reactivate highly engaged clients over time and better serve our clients; that our actions to make Stylists more visible to our clients will deepen relationships between clients and Stylists and increase client engagement; and our expectations regarding warehouse costs, transportation costs, gross margin, inventory levels, and advertising spend. These statements involve substantial risks and uncertainties, including risks and uncertainties related to the current macroeconomic environment; our ability to generate sufficient net revenue to offset our costs; consumer behavior; our ability to acquire, engage, and retain clients; our ability to provide offerings and services that achieve market acceptance; our data science and technology, Stylists, operations, marketing initiatives, and other key strategic areas; risks related to our inventory levels and management; risks related to our supply chain, sourcing of materials and shipping of merchandise; our ability to forecast our future operating results; and other risks described in the filings we make with the SEC. Further information on these and other factors that could cause our financial results, performance, and achievements to differ materially from any results, performance, or achievements anticipated, expressed, or implied by these forward-looking statements is included in filings we make with the SEC from time to time, including in the section titled "Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended August 3, 2024. These documents are available on the SEC Filings section of the Investor Relations section of our website at: https://investors.stitchfix.com . We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties, and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management's beliefs and assumptions only as of the date such statements are made.NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis CLLS (the "Company"), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million ("Tranche C") under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the "EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As a condition to the disbursement of Tranche C the Company issued 611,426 warrants to the benefit of the EIB, in accordance with the terms of the 14 th resolution of the shareholders' meeting held on June 28, 2024 and articles L. 228-91 and seq. of the French Commercial Code (the "Tranche C Warrants"). Each Tranche C Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of €1.70, corresponding to 99% of the volume-weighted average price of the Company's ordinary shares over the last 3 trading days preceding the decision of the board of directors of the Company to issue the Tranche C Warrants. The total number of shares issuable upon exercise of the Tranche C Warrants represent circa 0.6% of the Company's outstanding share capital as at their issuance date. Tranche C will mature six years from its disbursement date and will accrue interest at a rate of 6% per annum capitalized annually and payable at maturity. The other terms of the Tranche C Warrants and prepayment events of Tranche C under the Finance Contract are as set forth in the Company's press release of April 4, 2023 and Form 6-K filed with the U.S. Securities and Exchange Commission on such date. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN ® , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market CLLS and on Euronext Growth ALCLS . To find out more, visit our website: www.cellectis.com Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter) TALEN® is a registered trademark owned by Cellectis. Cautionary Statement This press release contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expect," "plan," and "will," or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the date of disbursement of the Tranche C and the use of the proceeds of amounts received under the Finance Contract. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with market conditions, and our ability to satisfy the conditions precedent under the Finance Contract. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC's website at www.sec.gov , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Interim Chief Financial Officer, investors@cellectis.com Attachment 20241128_Cellectis_BEI_Tranche C_ENGLISH_PR-MBT © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Donald Trump Is Returning to the World Stage. So Is His Trolling

Lawmakers react to Hunter Biden pardon

THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen

3 Reasons goeasy Is a Must-Buy for Long-Term Investors

COLUMBUS, Ga. , Dec. 2, 2024 /PRNewswire/ -- Aflac Incorporated AFL today announced that its Board of Directors has declared the first quarter dividend of $0.58 per share, payable on March 3, 2025 , to shareholders of record at the close of business on February 19, 2025 . This represents a 16.0% increase over the previously declared fourth quarter dividend. Commenting on the announcements, Aflac Incorporated Chairman and Chief Executive Officer Daniel P. Amos said: "I am pleased with the Board's action to increase the first quarter 2025 dividend. We treasure our record of 42 consecutive years of dividend increases, and our dividend track record is supported by the strength of our capital and cash flows. As an insurance company, our primary responsibility is to fulfill the promises we make to our policyholders. At the same time, we are listening to our shareholders and understand the importance of prudent liquidity and capital management. We remain committed to maintaining strong capital ratios on behalf of our policyholders and balance this financial strength with tactical capital deployment." Aflac Incorporated AFL , a Fortune 500 company, has helped provide financial protection and peace of mind for nearly seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan . In the U.S., Aflac is the No. 1 provider of supplemental health insurance products. 1 In Japan , Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force. The company takes pride in being there for its policyholders when they need us most, as well as being included in the World's Most Ethical Companies by Ethisphere for 18 consecutive years (2024), Fortune's World's Most Admired Companies for 23 years (2024) and Bloomberg's Gender-Equality Index for the fourth consecutive year (2023). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been included in the Dow Jones Sustainability North America Index (2023) for 10 years. To find out how to get help with expenses health insurance doesn't cover, get to know us at aflac.com or aflac.com/espanol. Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at investors.aflac.com under "Sustainability." 1 LIMRA 2023 U.S. Supplemental Health Insurance Total Market Report The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. The company desires to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as "expect," "anticipate," "believe," "goal," "objective," "may," "should," "estimate," "intends," "projects," "will," "assumes," "potential," "target," "outlook" or similar words as well as specific projections of future results, generally qualify as forward-looking. Aflac undertakes no obligation to update such forward-looking statements. The company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements: difficult conditions in global capital markets and the economy, including inflation defaults and credit downgrades of investments global fluctuations in interest rates and exposure to significant interest rate risk concentration of business in Japan limited availability of acceptable yen-denominated investments foreign currency fluctuations in the yen/dollar exchange rate differing interpretations applied to investment valuations significant valuation judgments in determination of expected credit losses recorded on the Company's investments decreases in the Company's financial strength or debt ratings decline in creditworthiness of other financial institutions the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners deviations in actual experience from pricing and reserving assumptions ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality or privacy of sensitive data residing on such systems subsidiaries' ability to pay dividends to the Parent Company inherent limitations to risk management policies and procedures operational risks of third-party vendors tax rates applicable to the Company may change failure to comply with restrictions on policyholder privacy and information security extensive regulation and changes in law or regulation by governmental authorities competitive environment and ability to anticipate and respond to market trends catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics (such as COVID-19), tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, terrorism or other acts of violence, and damage incidental to such events ability to protect the Aflac brand and the Company's reputation ability to effectively manage key executive succession changes in accounting standards level and outcome of litigation or regulatory inquiries allegations or determinations of worker misclassification in the United States Analyst and investor contact - David A. Young , 706.596.3264 or 800.235.2667 or dyoung@aflac.com Media contact – Ines Gutzmer , 762.207.7601 or igutzmer@aflac.com View original content to download multimedia: https://www.prnewswire.com/news-releases/aflac-incorporated-announces-16-0-increase-in-the-first-quarter-2025-dividend-302320084.html SOURCE Aflac Incorporated © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Notre Dame puts losing streak in past, turns focus to DartmouthMexico warns Trump-proposed tariffs to cost 400,000 US jobsUnited Nations has called on Taliban authorities to protect journalists and media workers as well as ensure that media outlets can operate freely, without restrictions or censorship, in Afghanistan. In a joint report titled Media Freedom in Afghanistan, released on Tuesday, the UN Mission in Afghanistan (UNAMA) and the UN Human Rights Office documented the increasing challenges faced by journalists, media workers, and outlets under the Taliban rule between August 2021 and September 2024. “Journalists and media workers in Afghanistan work under unclear rules on what they can and cannot report, running the risk of intimidation and arbitrary detention for perceived criticism, said Roza Otunbayeza, head of UNAMA. “For any country, a free press is not a choice, but a necessity. What we’re witnessing in Afghanistan is the systematic dismantling of this necessity”. The report titled Media Freedom in Afghanistan outlined 256 instances of arbitrary arrest and detention, combined with 130 cases of torture and ill-treatment. An additional 75 documented cases of threats and intimidation have created a climate of fear. In response, the Afghan foreign ministry denied having arrested that number of journalists, saying that those detained had committed a crime. Meanwhile, UN High Commissioner for Human Rights Volker Turk emphasized the broader implications of these restrictions. “Journalists and media workers are not just observers – they are essential to ensuring transparency and accountability, fostering informed debate, he said, adding that they are crucial in helping communities access vital information about humanitarian and protection issues that directly affect their lives. The report’s findings reveal that female media professionals face severe restrictions. Those who continue to work face discriminatory regulations affecting everything from dress codes to which stories they can cover. During the daily media briefing at UN Headquarters, Deputy Spokesperson Farhan Aziz Haq highlighted this gender dimension: “Women journalists and media workers face particular discriminatory measures that limit their ability to do their work”. Ms. Otunbayeza also urged the de facto authorities to “fully recognize the importance of women working in the media sector”. The report also warns of the broader consequences of diminishing international support for Afghanistan’s media sector. “Technical and financial support for the media sector in Afghanistan, and thereby standing behind the importance of freedom of expression and public debate is instrumental for growth of the country,” Ms. Otunbayeza concluded. Looking forward, the UN is calling on the Taliban authorities to honour Afghanistan’s obligations under the International Covenant on Civil and Political Rights, which guarantees freedom of expression without discrimination. The report emphasizes that free press is essential not just for transparency and accountability but for the country’s social and economic development.